5 Best Performing Stocks of Q1 2026 to Watch for Q2

Page 1 of 5

In this article, we are going to look at the 5 Best Performing Stocks of Q1 2026 to Watch for Q2. For a longer list and more details on how we picked these stocks, you can go to 10 Best Performing Stocks of Q1 2026 to Watch for Q2.

5. Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Q1 2026 Performance: 152.25%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best-performing stocks of Q1 2026 to watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its Buy rating on the stock.

This increase in valuation came after Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement under which it will acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Enliven Therapeutics, Inc.’s (NASDAQ:ELVN) competitor, through a subsidiary for approximately $6.7 billion.

5 Best Performing Stocks of Q1 2026 to Watch for Q2

Stocks

Earlier, on March 24, Mizuho also lifted its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $41 to $45 and maintained its Outperform rating on the stock.

The research firm pointed to recent Phase 1b data for ELVN-001 as the key factor for this increase in the price target. Mizuho sees Enliven Therapeutics, Inc. (NASDAQ:ELVN) as an under-rated asset in the chronic myeloid leukemia market. The firm added that it expects more data from ELVN-001’s Phase 1a/b trial in mid-year.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for cancer treatment.

Page 1 of 5